Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Completed 4Active not recruiting 3Recruiting 2Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Thoracic 2

Conditions

Pancreatic Neoplasms 71Breast Neoplasms 45Neoplasms 29Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 21Neoplasm Metastasis 14Adenocarcinoma 13Squamous Cell Carcinoma of Head and Neck 8Lung Neoplasms 8Colorectal Neoplasms 8Melanoma 7Carcinoma 7Head and Neck Neoplasms 6Digestive System Neoplasms 6Cholangiocarcinoma 6Small Cell Lung Carcinoma 5Pancreatic Diseases 5Pancreatic Adenocarcinoma 5Ovarian Neoplasms 5Digestive System Diseases 5Carcinoma, Pancreatic Ductal 5Stomach Neoplasms 4Sarcoma 4Recurrence 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms by Site 4Gallbladder Neoplasms 4Fallopian Tube Neoplasms 4Endocrine Gland Neoplasms 4Carcinoma, Squamous Cell 4

Interventions

pembrolizumab 124Cisplatin 27lenvatinib 24Carboplatin 24Paclitaxel 19Docetaxel 16Fluorouracil 13Capecitabine 11Pemetrexed 10Gemcitabine 10Saline Solution 8Oxaliplatin 8epacadostat 6Leucovorin 5Irinotecan 5Cetuximab 5olaparib 4Bevacizumab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3regorafenib 3enzalutamide 3durvalumab 3Nivolumab 3Etoposide 3trametinib 2etoposide phosphate 2dabrafenib 2Tretinoin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × 130-nm albumin-bound paclitaxel × Clear all
NCT03396445 2025-11-05

MK-5890-001

Merck Sharp & Dohme LLC

Phase 1 Completed
182 enrolled 36 charts
BreastThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 41 charts 1 FDA
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02775435 2024-10-08

KEYNOTE-407

Merck Sharp & Dohme LLC

Phase 3 Completed
559 enrolled 18 charts 1 FDA
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02622074 2020-09-10

KEYNOTE 173

Merck Sharp & Dohme LLC

Phase 1 Completed
60 enrolled 26 charts
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡